Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heparin Investigation Highlights Foreign Inspection Gap – Former FDA Officials

This article was originally published in PharmAsia News

Executive Summary

Members of Congress have jumped on the reported admission by U.S. FDA that it did not inspect a Changzhou City, China plant that provides active pharmaceutical ingredients for Baxter Healthcare's injectable heparin as a symbol of FDA's inability to adequately inspect pharmaceuticals manufactured abroad
Advertisement

Related Content

China Biologic Renews GMP Certification Under Stiffer SFDA GMP Rules
U.S. Mulls Registration Fees For Foreign Drug Manufacturers
China State FDA Issues Warning In Wake Of Heparin Safety Concerns
Congressional Leaders To Consider “Emergency Legislation” In Wake Of Heparin Safety Scare
With Overstretched FDA, Companies Advised To Conduct Their Own Foreign Inspections – Former FDA Chief Counsel
Chinese Heparin API Manufacturer Not Inspected By SFDA
U.S. FDA’s Response To Heparin Scare Made With “Alacrity And Sound Judgment” – von Eschenbach
Congressman Calls For Resignation Of U.S. FDA Commissioner In Wake Of Latest Chinese Safety Scare
Congressman Calls For Resignation Of U.S. FDA Commissioner In Wake Of Latest Chinese Safety Scare
Import Safety Agreement Further Entwines FDA/China Regulatory Process
Advertisement
UsernamePublicRestriction

Register

SC067666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel